JANICE BROWN, MD
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California G064476
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 723-4000
Organization information
See more information about JANICE BROWN at bizstanding.comJanice Brown MD
300 Pasteur Dr, Stanford, CA 94305
Industry:
Internist
Phone:
(650) 723-9729 (Phone)
Janice Marie Yu Brown
Professional information
Dr. Janice Brown, Stanford CA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
Stanford Blood/Marrow Transplnt
300 Pasteur Dr STE H0101, Stanford 94305
(650) 723-0822 (Phone)
300 Pasteur Dr STE H0101, Stanford 94305
(650) 723-0822 (Phone)
Certifications:
Infectious Disease, 1994, Internal Medicine, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Stanford Blood/Marrow Transplnt
300 Pasteur Dr STE H0101, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
300 Pasteur Dr STE H0101, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
University of Virginia / Main Campus
Graduated: 1987
Stanford U Med Ctr
University of Virginia / Main Campus
Graduated: 1987
Stanford U Med Ctr
Janice M Brown, Stanford CA
Specialties:
Internist
Address:
300 Pasteur Dr, Stanford, CA 94305
Education:
University of Virginia, School of Medicine - Doctor of Medicine
Stanford Hospital & Clinics - Residency - Internal Medicine
Stanford Hospital & Clinics - Residency - Internal Medicine
Therapeutic Uses Of Allogeneic Myeloid Progenitor Cells
US Patent:
2011005, Mar 3, 2011
Filed:
Sep 2, 2010
Appl. No.:
12/875022
Inventors:
Janice Marie Brown - Stanford CA, US
International Classification:
A61K 35/12, A61P 37/00
US Classification:
424 937
Abstract:
Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.
Therapeutic Uses Of Allogeneic Myeloid Progenitor Cells
US Patent:
7811815, Oct 12, 2010
Filed:
Nov 8, 2005
Appl. No.:
11/270710
Inventors:
Janice Marie Brown - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12N 5/00, C12N 5/02, C12N 5/071
US Classification:
435325, 435366, 4353721
Abstract:
Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.